Eli Lilly’s Mounjaro peak sales could now top $68B – analyst; Elon Musk’s brain-chip company reels in $280M

A few months ago, BMO Cap­i­tal an­a­lyst Evan Seiger­man es­ti­mat­ed Eli Lil­ly’s type 2 di­a­betes drug Moun­jaro would have more than $50 bil­lion in peak sales. On Tues­day, he bumped that es­ti­mate up to $68.7 bil­lion.

One rea­son for the boost? Lil­ly re­port­ed Moun­jaro’s con­sen­sus-bust­ing sales in its sec­ond-quar­ter earn­ings on Tues­day, along with an an­tic­i­pat­ed FDA ap­proval in obe­si­ty this year and his as­sess­ment of the drug’s “un­in­hib­it­ed” de­mand.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.